Company: PTHS
Filing Date: 2025-08-28
Form Type: S-3
Source: 0001753926-25-001403
Chunk: 63

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-28
Form: S-3
Chunk 63
---
 slowdowns or stoppages and disruptions in delivery systems, interruption or delays to discovery and development pipelines and difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols.

The extent to which the emergence of new variants of COVID-19, or any other outbreak of a pandemic or epidemic disease, impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain our impact. Further, to the extent any pandemic or epidemic disease adversely affects our business and financial results, we may also have the effect of heightening many of the other risks described in this section.

The biopharmaceutical industry may be negatively affected by federal government deficit reduction policies, which could reduce the value of ZELSUVMI.

In an effort to contain the U.S. federal deficit, the biopharmaceutical industry could be considered a potential source of savings and could be the target of legislative proposals aimed at reducing federal expenditures. Government action to reduce U.S. federal spending on entitlement programs, including Medicare, Medicaid or other publicly funded or subsidized health programs, or to lower drug spending, may affect payment for ZELSUVMI. These and any other cost controls or any significant additional taxes or fees that may be imposed on the biopharmaceutical industry as part of deficit reduction efforts could reduce cash flows and adversely affect our business, financial condition or results of operations.

<div align='center'>33

THE OFFERING</div>

| Company                                                      
 Common Stock offered by the Selling Stockholders:            | This                                                                                                                          
 prospectus relates to 8,137,868 shares of Company Common Stock that may be sold from time to time by the Selling Stockholders 
 named in this prospectus.                                                                                                     |
| Company                                                      
 Common Stock outstanding at commencement of the offering(1): | 3,042,143                                                                                                                     
 shares of Company Common Stock.                                                                                               |
| Use                                                          
 of proceeds:                                                 | We                                                                                                                            
 will not receive any proceeds from the sales of outstanding shares of Common Stock by the Selling Stockholders.               |
| Risk                                                         
 factors:                                                     | Investing                                                                                                                     
 in our Company Common Stock involves a high degree of risk. See “Risk factors” beginning on page                              
 7  of this     prospectus for a discussion of some of the factors you should carefully consider before                        
 deciding to invest in our Company     Common Stock.                                                                           |
| Trading                                                      
 market and symbol: